Two decades with omalizumab: what we still have to learn
Cristoforo Incorvaia,1 Marina Mauro,2 Elena Makri,1 Gualtiero Leo,3 Erminia Ridolo4 1Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy; 2Allergy Department, Sant’Anna Hospital, Como, Italy; 3Pediatric Allergy and Respiratory Pathophysiology Unit, Department of Pediatrics, Vitto...
Guardado en:
Autores principales: | Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e51206bb0cc247e390730552dd1f244d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Davide Stefano Sardina, et al.
Publicado: (2021) -
Anticuerpo monoclonal anti-inmunoglobulina E en el tratamiento de la rinitis alérgica
por: Naser G,Alfredo, et al.
Publicado: (2011) -
Hyper ige syndrome associated with novel dock8 heterozygous mutation: а case report
por: D. V. Osypchuk, et al.
Publicado: (2020) -
Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
por: Catherine King, et al.
Publicado: (2021) -
Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children
por: Paola Di Filippo, et al.
Publicado: (2021)